Comparison · NCT04164901-deaths
Vorasidenib vs Matching Placebo: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Vorasidenib vs Matching Placebo: deaths from any cause. Trial comparisons, record NCT04164901-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04164901-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0 | 0.0225 | wilson | |
| Risk in group 2 | 0 | 0 | 0.023 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.023 | 0.0225 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to harm | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Vorasidenib | Vorasidenib 40 mg, continuous daily dosing.~Vorasidenib: Vorasidenib oral film-coated tablets~One subject in the vorasidenib arm withdrew consent prior to treatment and did not receive the study drug; as a consequence the number of subjects in this group is 167 | 0 | 167 | EG000 |
| Group 2 | Matching Placebo | Matching placebo 40 mg, continuous daily dosing.~Matching Placebo: Matching Placebo oral tablets~The data reflects the subjects assigned to placebo, prior to the placebo group being eligible to cross over to receive Vorasidenib, which was an option after the study was unblinded. | 0 | 163 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- Approximately 30 months
Source ClinicalTrials.gov
Trial
- Title
- Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)
- NCT number
- NCT04164901
- Phases
- PHASE3
- Conditions
- Grade 2 Glioma, Residual Glioma, Recurrent Glioma
- Interventions
- Vorasidenib, Matching Placebo
- Lead sponsor
- Institut de Recherches Internationales Servier
- Results first posted
- 2023-11-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04164901?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04164901-deaths